glp-1 patent pharmaindustry #glp1 #patentcliff #obesitytreatment #diabetescare #indianpharma #biologics As Novo's patent expires, GLP-1

We believe in using natures best to support your anti-aging journey

It helps maintain our mobility, balance and strength

While you may worry about regaining weight after stopping semaglutide, its not a guarantee

Additionally, some individuals may require adjustments in dosage over time to continue seeing progress

Predictors of 15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4

Unlike California and Pennsylvania, which provide broad coverage for all obesity-indicated GLP-1s, Kentuckys Medicaid program covers only Wegovy for weight management alongside Type 2 diabetes-indicated medications